March 16, 2023– Syneron Tech, an AI-powered synthetic peptide new drug R&D company incubated by Sinovation Ventures，recently closed a multi-million-dollar Pre-A financing round, co-led by Lenovo Capital and Gree Capital. Before that, Syneron Tech had successively received seed round and angel round investments from three funds of Sinovation Ventures.
Dr. Kai-Fu Lee, Chairman and CEO of Sinovation Ventures, noted that Sinovation Ventures has always focused on technological breakthroughs arising from the intersection of AI for Science. He expressed optimism for Syneron Tech's journey to become a global leader in AI-driven pharmaceuticals. Mr. Ren Bobing, Executive Director of Sinovation Ventures, praised the company’s closed-loop dry and wet validation approach and strong execution capabilities in industrial implementation.
Funded by Dr. Zhang Xiao and Professor Gao Xin, Syneron Tech brings together top-tier talents in the interdisciplinary fields of bio-medicine and AI. The company has developed SynCore, a multi-target generative AI design platform for synthetic peptide drugs, achieving a 92% accuracy in membrane permeability prediction. Focusing on First-In-Class pipelines, Syneron Tech is committed to providing breakthrough solutions to the global biomedical industry through its innovative AI+synthetic peptide technology.
Dr. Zhang Xiao, Co-founder and CEO of Syneron Tech
Prof. Gao Xin, Co-founder and CAIO of Syneron Tech